Replies to post #216087 on Biotech Values

[xavierprivas]

IMO MRNS ganax probably won't work in PPD. MRNS ganax efficacy is pretty
weak vs SAGE-547 or SAGE-217. This analysis by Ohad Hammer is pretty old but probably still applies.

http://www.orf-blog.com/sage-and-marinus-not-the-typical-cns-story/

For the last two years, MRNS more or less is doing trial for orphan
indication with N < 10. They seem to take forever to do this MDD trial

https://clinicaltrials.gov/ct2/show/NCT02900092?term=Ganaxolone&draw=2&rank=14

which started in Nov 2016 and ending in Jan 2019. At the last update Oct 2017
they managed to enroll 10.

MRNS was a good short term trade. In July I got in @1.53, sold it quickly
2 months later for @3.06. At this price, I am not sure if it is a good
short term trade.